In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on CVRx (CVRX – Research Report), with a price target of $21.00. The company’s shares closed yesterday at $13.62.
O’Brien covers the Healthcare sector, focusing on stocks such as Sight Sciences, Insulet, and Stryker. According to TipRanks, O’Brien has an average return of 0.2% and a 45.20% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVRx with a $18.75 average price target, a 37.67% upside from current levels. In a report released on October 27, Canaccord Genuity also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
CVRX market cap is currently $283.3M and has a P/E ratio of -6.62.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is neutral on the stock. Last month, Galle Liz, the VP OF GLOBAL CLINICAL RESEARCH of CVRX bought 778.00 shares for a total of $178.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVRx (CVRX) Company Description:
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
Read More on CVRX:
- CVRx price target lowered to $16 from $23 at Canaccord
- CVRx reports Q3 EPS (43c), consensus (58c)
- CVRx Reports Third Quarter 2023 Financial and Operating Results
- CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
- CVRx management to meet with Craig-Hallum
